Study of PARP Inhibitor Treatment Effects and Dose Management in Patients Over 70 with Advanced Ovarian Cancer

What this Trial Is About

Researchers are studying the use of PARP inhibitors, a type of anti-cancer treatment that targets tumor cells, in patients aged 70 years and older with advanced ovarian cancer. This study aims to understand how various clinical, biological, and geriatric factors affect the relative dose intensity RDI of PARP inhibitor therapy in this elderly population. The goal is to gather real-life data to help guide treatment decisions and manage side effects that may impact therapy continuation. The study involves elderly patients starting maintenance therapy with PARP inhibitors for the first time, including Olaparib which may be given with Bevacizumab and Niraparib. These treatments are administered according to approved guidelines. There are no special study visits patients receive routine care, and medical data about disease follow-up is collected at inclusion and every three months for one year. Quality of life surveys OV28 and ELD14 and a geriatric assessment G-CODE are completed every three months, and blood samples are taken at inclusion, six months, and twelve months to analyze genetic factors related to treatment toxicity. Participants are followed for 12 months with regular assessments including medical evaluations, surveys, and blood tests to monitor treatment effects and side effects. Researchers will measure the relative dose intensity of PARP inhibitors at 12 months and evaluate quality of life and geriatric health over time. Genetic testing aims to identify signatures linked to toxicity. This monitoring helps optimize management of therapy-related adverse events and supports treatment adherence in older patients.

Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer